Cost/effectiveness of elivaldogene autotemcel vs. hematopoietic stem cells transplantation in patients with cerebral adrenoleukodystrophy (CALD)
AbstractCerebral adrenoleukodystrophy (CALD) is a severe, rare neurological disease with a progressive course and poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) is still considered the standard of care for CALD. Elivaldogene autotemcel is a novel gene therapy for the treat...
Main Authors: | Minela Vapljanin Muratović, Miloš Milosavljević, Slobodan Janković |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-04-01
|
Series: | Biotechnology & Biotechnological Equipment |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/13102818.2024.2342888 |
Similar Items
-
Elivaldogene autotemcel approved for treatment of cerebral adrenoleukodystrophy (CALD) in males: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
by: Anna I. Scott, et al.
Published: (2023-01-01) -
Multiple sclerosis in an adrenoleukodystrophy carrier
by: Thomas Jenkins, et al.
Published: (2011-11-01) -
Evaluation of Neurofilament Light Chain as a Biomarker of Neurodegeneration in X-Linked Childhood Cerebral Adrenoleukodystrophy
by: Hongge Wang, et al.
Published: (2022-03-01) -
Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future
by: Ann B. Moser, et al.
Published: (2022-02-01) -
Clinical and Genetic Analysis of Adrenoleukodystrophy in Adults
by: WANG Mengwen, et al.
Published: (2022-04-01)